|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Consistently, forcing global DNA demethylation of SCC-TAFs with 5-AZA rescued TGF-β1/SMAD3 activation, whereas genetic downregulation of SMAD3 in ADC-TAFs and control fibroblasts increased TGF-β1/SMAD2 activation, and reduced their fibrotic phenotype and antitumor responses to nintedanib in vitro and in vivo.
|
31694906 |
2020 |
|
Squamous cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma.
|
31694906 |
2020 |
|
Atresia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we identified miR-181a as a central component of activin/Smad3-mediated follicle atresia. miR-181a was strikingly upregulated in porcine atretic follicles, which induced the apoptosis of porcine granulosa cells (GCs) in vitro.
|
31574295 |
2020 |
|
airway disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dichotomous role of TGF-β controls inducible regulatory T-cell fate in allergic airway disease through Smad3 and TGF-β-activated kinase 1.
|
31626843 |
2020 |
|
Bone Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.
|
31788114 |
2019 |
|
Cerebral Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, overexpression of miR‑323 directly targeted and suppressed SMAD3 expression in the in vitro model of cerebral infarction, while inhibition of miR‑323 induced SMAD3 expression.
|
30535466 |
2019 |
|
Epilepsy, Temporal Lobe
|
0.010 |
Biomarker
|
disease |
BEFREE |
Smad Anchor for Receptor Activation and Phospho-Smad3 Were Upregulated in Patients with Temporal Lobe Epilepsy.
|
30847724 |
2019 |
|
Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, these findings define a mechanism by which 1, 25-(OH)<sub>2</sub>D<sub>3</sub> reduces ECM accumulation and suppresses the TGF-β-SMAD3-VDR pathway in HTMCs, thus protecting the cells from oxidative stress, suggesting 1, 25-(OH)<sub>2</sub>D<sub>3</sub> might be a potential therapeutic for glaucoma.
|
31196627 |
2019 |
|
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
SMAD3-dependent and -independent pathways in glomerular injury associated with experimental glomerulonephritis.
|
31141397 |
2019 |
|
Hepatitis
|
0.010 |
AlteredExpression
|
group |
BEFREE |
We found that DEHP exposure remarkably promoted liver inflammation, necrosis and fibrosis, and increased expression of the protein associated with liver inflammation and fibrogenesis, including α-SMA, COL-Ⅰ, COL-Ⅲ, TGF-β1, P-Smad2, P-Smad3, P-p38 and P-p65.
|
30884453 |
2019 |
|
Kidney Failure, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was also found that acupuncture significantly reduced the levels of TNF‑α, Smad3, ILK and TGF‑β expression, dramatically decreased the concentrations of TGF‑β, IL‑8, TNF‑α and IL‑1β in blood serum, and significantly increased eNOS expression in the CRF model rabbits by affecting the TGF‑β/Smad signaling pathway.
|
31322212 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Inhibition of microRNA-221-5p induces osteogenic differentiation by directly targeting smad3 in myeloma bone disease mesenchymal stem cells.
|
31788114 |
2019 |
|
Psychological pseudocyesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this study, we measured the expression of TGF-β1, TGF-β receptor type I (TβRI), Smad3 and p-Smad3 in the endometrium of mice and observed their elevation on day 4, 5 and 6 of pseudopregnancy.
|
31845233 |
2019 |
|
Respiratory Distress Syndrome, Adult
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, puerarin alleviated the inflammatory response resulting from pulmonary fibrosis by regulating the TGF-ß1/Smad3 pathway in infants with ARDS.
|
31471534 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that the MALAT1/hsa-miR-346/SMAD3 regulatory network plays a key role in the development of sepsis, and may serve as a target for the treatment of sepsis.
|
31494280 |
2019 |
|
Skin lesion
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The reduced progression of skin sclerosis in PGRN-deficient mice was associated with down-regulation of transforming growth factor (TGF)-β receptor I (TβR I) and decreased level of phosphorylated Smad3, with correspondingly impaired expression of its downstream target gene connective tissue growth factor (CTGF) in skin lesion.
|
31108104 |
2019 |
|
Hallopeau-Siemens Disease
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Knockdown of TSP1 reduced phosphorylation of smad3 (a downstream target of TGF-β signaling) in RDEB primary fibroblasts, whereas overexpression of collagen VII reduced phosphorylation of smad3.
|
30684555 |
2019 |
|
Obstructive nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transforming growth factor-β1 (TGF-β1)/Smad3-driven renal fibrosis is the common pathogenesis of obstructive nephropathy.
|
31211499 |
2019 |
|
Adenocarcinoma of rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
TIPE2 overexpression decreased autophagy by reducing the expression levels of p-Smad2, p-Smad3, and transforming growth factor-beta (TGF-β) in rectal adenocarcinoma cells, however, TIPE2 knockdown showed opposite effects.
|
30637920 |
2019 |
|
Hyperuricemic nephropathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, PTE suppressed the activation of TGF-β1/Smad3, Src and STAT3 signaling pathway to alleviate renal fibrosis of HN mice, highlighting that PTE was a potential antifibrotic strategy for hyperuricemic nephropathy.
|
30551434 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that the MALAT1/hsa-miR-346/SMAD3 regulatory network plays a key role in the development of sepsis, and may serve as a target for the treatment of sepsis.
|
31494280 |
2019 |
|
Sclerosis of the skin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The reduced progression of skin sclerosis in PGRN-deficient mice was associated with down-regulation of transforming growth factor (TGF)-β receptor I (TβR I) and decreased level of phosphorylated Smad3, with correspondingly impaired expression of its downstream target gene connective tissue growth factor (CTGF) in skin lesion.
|
31108104 |
2019 |
|
Malignant Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we aimed to explore the effect and mechanism of Mothers against decapentaplegic homologue (SMAD3) silencing in sensitizing malignant glioma to radiotherapy.
|
30535026 |
2019 |
|
Hypertrophic pachymeningitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
TGF-<i>β</i>1/SMAD2/SMAD3 pathway is critical in HP and is a potential novel therapeutic target.
|
30911567 |
2019 |
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compound Astragalus and Salvia miltiorrhiza extract (CASE), containing astragalosides, astragalus polysaccharide extracted from Astragalus membranaceus (Fisch.)Bge. and salvianolic acids from Salvia miltiorhiza Bge., has been found to inhibit hepatocarcinogenesis via mediating transforming growth factor-β (TGF-β)/Smad signaling, especially Smad3 phosphorylation.
|
30412748 |
2019 |